The αlpha-7 nicotinic acetylcholine receptor (α7nAChR) is a central mediator of the cholinergic anti-inflammatory pathway and has emerged as a promising therapeutic target in various conditions, such as sepsis, arthritis, metabolic dysfunction, and atherosclerosis. Here, PSMA3 is linked to atherosclerosis.